In fact, in leukemic context, AML-EVs can reprogram mesenchymal stem cells (MSCs) and stromal cells, and down-regulate niche retention factor stromal cell-derived factor 1 (SDF1), resulting in mobilization of HSPCs from BM. This evidence concerns the gene CXCL12 and acute myeloid leukemia.